CAH vs STRO · P/E 35, rev $222.58B vs rev $62.0M
Cardinal Health Inc (CAH) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CAH revenue for 2025-06-30 was $222.58B. Net income was $1.57B. Revenue was down 1.9% from 2024-06-30 to 2025-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CAH currently screens at market cap $53.00B and trailing P/E 34.6. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CAH and STRO stock pages for the full models.
Not investment advice.